# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
AbbVie impresses with Q1 results: EPS beats at $2.31 (-6.1% Y/Y), net revenue exceeds at $12.31 billion (+0.7%). Notable: Immun...
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Landos Biopharma (NASDAQ:LABP) from Buy to Neutral and lowers ...
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Monday. The Dow traded down 0....
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday. The Dow trad...
AbbVie seals deal with Landos Biopharma at $20.42/share, totaling $137.5 million plus CVR. Acquisition targets NX-13, promising...
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 50 points on Monday. Following the market op...